Latest current assets for TSHA: $280M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Taysha Gene Therapies (TSHA) currently reports a current assets of $280M as of March 2026. That compares with $120M in the prior-year period — up 133.8% year over year. Use the charts on this page to explore Taysha Gene Therapies's current assets history and peer comparisons.
Taysha Gene Therapies's current assets increased from $120M to $280M — a 133.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Taysha Gene Therapies reported $280M in current assets as of March 2026. That compares with $120M in the prior-year period — up 133.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current current assets of $280M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Taysha Gene Therapies, and consider following TSHA for alerts when major investors trade the stock.
Taysha Gene Therapies is classified in the Healthcare sector. On current assets, it currently shows $280M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TSHA with unrelated industries.